In 2012, Srivastava et al. screened serum samples aiming to identify CNS-specific antibodies in MS, and identified the glial potassium channel Kir4.1 as one of the serum immune targets in patients with MS. This evidence concerns the gene KCNJ10 and myeloid sarcoma.